Antisense And RNAi Therapeutics Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology (RNA Interference, Antisense RNA), By Application (Ocular, Cardiometabolic & Renal Disorders, Cancer, Respiratory Disorders, Skin Diseases, Neurodegenerative Disorders, Genetic Disorders, Infectious Diseases), By Route of Administration (Intravenous Injections, Intrathecal Injections, Subcutaneous Injections, Other), By Region and Competition, 2020-2030F
The Global Antisense And RNAi Therapeutics Market, valued at USD 5.20 Billion in 2024, is projected to experience a CAGR of 19.19% to reach USD 14.91 Billion by 2030. Antisense and RNAi therapeutics represent a molecular medicine class that precisely modulates gene expression by either inhibiting protein production via antisense oligonucleotides or degrading messenger RNA through RNA interference, offering targeted interventions for various diseases. The market's expansion is fundamentally driven by the rising global incidence of genetic and chronic disorders, alongside a burgeoning understanding of intricate molecular disease mechanisms enabling highly specific therapeutic design. Growing investments in research and development further propel this growth by expanding the addressable therapeutic landscape for conditions with limited treatment options.
Key Market Drivers
The global Antisense and RNAi Therapeutics Market is significantly influenced by the increasing burden of genetic and chronic diseases, which establishes a profound unmet medical need for innovative treatments. These therapies offer precise modulation of gene expression, addressing the root causes of many disorders where conventional treatments fall short. The substantial patient population suffering from these conditions drives consistent demand for novel therapeutic avenues.
Key Market Challenges
The persistent complexity in achieving efficient and precisely targeted *in vivo* delivery of nucleic acid-based molecules to specific cells and tissues directly impedes the growth of the Global Antisense and RNAi Therapeutics Market. This challenge arises from the inherent properties of these molecules, such as their size, negative charge, and susceptibility to enzymatic degradation, which hinder their ability to cross biological barriers and reach their intracellular targets in sufficient concentrations. Consequently, the development of novel therapies is prolonged due to the extensive research required for suitable delivery vehicles, increasing overall development costs and time to market.
Key Market Trends
Antisense and RNAi therapeutics are increasingly expanding into broader therapeutic areas beyond rare diseases. This strategic diversification involves targeting more prevalent chronic conditions such as cardiovascular, metabolic, and neurological disorders, indicating a growing confidence in the technology's applicability to larger patient populations.
Key Market Players
In this report, the Global Antisense And RNAi Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies presents in the Global Antisense And RNAi Therapeutics Market.
Available Customizations:
Global Antisense And RNAi Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Key Market Drivers
The global Antisense and RNAi Therapeutics Market is significantly influenced by the increasing burden of genetic and chronic diseases, which establishes a profound unmet medical need for innovative treatments. These therapies offer precise modulation of gene expression, addressing the root causes of many disorders where conventional treatments fall short. The substantial patient population suffering from these conditions drives consistent demand for novel therapeutic avenues.
Key Market Challenges
The persistent complexity in achieving efficient and precisely targeted *in vivo* delivery of nucleic acid-based molecules to specific cells and tissues directly impedes the growth of the Global Antisense and RNAi Therapeutics Market. This challenge arises from the inherent properties of these molecules, such as their size, negative charge, and susceptibility to enzymatic degradation, which hinder their ability to cross biological barriers and reach their intracellular targets in sufficient concentrations. Consequently, the development of novel therapies is prolonged due to the extensive research required for suitable delivery vehicles, increasing overall development costs and time to market.
Key Market Trends
Antisense and RNAi therapeutics are increasingly expanding into broader therapeutic areas beyond rare diseases. This strategic diversification involves targeting more prevalent chronic conditions such as cardiovascular, metabolic, and neurological disorders, indicating a growing confidence in the technology's applicability to larger patient populations.
Key Market Players
- Olix Pharmaceuticals, Inc.
- GSK plc
- Sanofi Aventis S.A.
- Alnylam Pharmaceuticals, Inc.
- Ionis Pharmaceuticals, Inc.
- Benitec Biopharma Inc
- Silence Therapeutics Inc.
- Arbutus Biopharma Inc.
- Sarepta Therapeutics Inc.
- Percheron Therapeutics Limited.
In this report, the Global Antisense And RNAi Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- Antisense And RNAi Therapeutics Market, By Technology:
- RNA Interference
- Antisense RNA
- Antisense And RNAi Therapeutics Market, By Route of Administration:
- Intravenous Injections
- Intrathecal Injections
- Subcutaneous Injections
- Other
- Antisense And RNAi Therapeutics Market, By Application:
- Ocular
- Cardiometabolic & Renal Disorders
- Cancer
- Respiratory Disorders
- Skin Diseases
- Neurodegenerative Disorders
- Genetic Disorders
- Infectious Diseases
- Antisense And RNAi Therapeutics Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Company Profiles: Detailed analysis of the major companies presents in the Global Antisense And RNAi Therapeutics Market.
Available Customizations:
Global Antisense And RNAi Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL ANTISENSE AND RNAI THERAPEUTICS MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Technology (RNA Interference, Antisense RNA)
5.2.2. By Route of Administration (Intravenous Injections, Intrathecal Injections, Subcutaneous Injections, Other)
5.2.3. By Application (Ocular, Cardiometabolic & Renal Disorders, Cancer, Respiratory Disorders, Skin Diseases, Neurodegenerative Disorders, Genetic Disorders, Infectious Diseases)
5.2.4. By Region
5.2.5. By Company (2024)
5.3. Market Map
6. NORTH AMERICA ANTISENSE AND RNAI THERAPEUTICS MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Technology
6.2.2. By Route of Administration
6.2.3. By Application
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Antisense And RNAi Therapeutics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Technology
6.3.1.2.2. By Route of Administration
6.3.1.2.3. By Application
6.3.2. Canada Antisense And RNAi Therapeutics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Technology
6.3.2.2.2. By Route of Administration
6.3.2.2.3. By Application
6.3.3. Mexico Antisense And RNAi Therapeutics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Technology
6.3.3.2.2. By Route of Administration
6.3.3.2.3. By Application
7. EUROPE ANTISENSE AND RNAI THERAPEUTICS MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Technology
7.2.2. By Route of Administration
7.2.3. By Application
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Antisense And RNAi Therapeutics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Technology
7.3.1.2.2. By Route of Administration
7.3.1.2.3. By Application
7.3.2. France Antisense And RNAi Therapeutics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Technology
7.3.2.2.2. By Route of Administration
7.3.2.2.3. By Application
7.3.3. United Kingdom Antisense And RNAi Therapeutics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Technology
7.3.3.2.2. By Route of Administration
7.3.3.2.3. By Application
7.3.4. Italy Antisense And RNAi Therapeutics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Technology
7.3.4.2.2. By Route of Administration
7.3.4.2.3. By Application
7.3.5. Spain Antisense And RNAi Therapeutics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Technology
7.3.5.2.2. By Route of Administration
7.3.5.2.3. By Application
8. ASIA PACIFIC ANTISENSE AND RNAI THERAPEUTICS MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Technology
8.2.2. By Route of Administration
8.2.3. By Application
8.2.4. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Antisense And RNAi Therapeutics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Technology
8.3.1.2.2. By Route of Administration
8.3.1.2.3. By Application
8.3.2. India Antisense And RNAi Therapeutics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Technology
8.3.2.2.2. By Route of Administration
8.3.2.2.3. By Application
8.3.3. Japan Antisense And RNAi Therapeutics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Technology
8.3.3.2.2. By Route of Administration
8.3.3.2.3. By Application
8.3.4. South Korea Antisense And RNAi Therapeutics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Technology
8.3.4.2.2. By Route of Administration
8.3.4.2.3. By Application
8.3.5. Australia Antisense And RNAi Therapeutics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Technology
8.3.5.2.2. By Route of Administration
8.3.5.2.3. By Application
9. MIDDLE EAST & AFRICA ANTISENSE AND RNAI THERAPEUTICS MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Technology
9.2.2. By Route of Administration
9.2.3. By Application
9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Antisense And RNAi Therapeutics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Technology
9.3.1.2.2. By Route of Administration
9.3.1.2.3. By Application
9.3.2. UAE Antisense And RNAi Therapeutics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Technology
9.3.2.2.2. By Route of Administration
9.3.2.2.3. By Application
9.3.3. South Africa Antisense And RNAi Therapeutics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Technology
9.3.3.2.2. By Route of Administration
9.3.3.2.3. By Application
10. SOUTH AMERICA ANTISENSE AND RNAI THERAPEUTICS MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Technology
10.2.2. By Route of Administration
10.2.3. By Application
10.2.4. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Antisense And RNAi Therapeutics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Technology
10.3.1.2.2. By Route of Administration
10.3.1.2.3. By Application
10.3.2. Colombia Antisense And RNAi Therapeutics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Technology
10.3.2.2.2. By Route of Administration
10.3.2.2.3. By Application
10.3.3. Argentina Antisense And RNAi Therapeutics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Technology
10.3.3.2.2. By Route of Administration
10.3.3.2.3. By Application
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. GLOBAL ANTISENSE AND RNAI THERAPEUTICS MARKET: SWOT ANALYSIS
14. PORTER'S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. COMPETITIVE LANDSCAPE
15.1. Olix Pharmaceuticals, Inc.
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. GSK plc
15.3. Sanofi Aventis S.A.
15.4. Alnylam Pharmaceuticals, Inc.
15.5. Ionis Pharmaceuticals, Inc.
15.6. Benitec Biopharma Inc
15.7. Silence Therapeutics Inc.
15.8. Arbutus Biopharma Inc.
15.9. Sarepta Therapeutics Inc.
15.10. Percheron Therapeutics Limited.
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL ANTISENSE AND RNAI THERAPEUTICS MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Technology (RNA Interference, Antisense RNA)
5.2.2. By Route of Administration (Intravenous Injections, Intrathecal Injections, Subcutaneous Injections, Other)
5.2.3. By Application (Ocular, Cardiometabolic & Renal Disorders, Cancer, Respiratory Disorders, Skin Diseases, Neurodegenerative Disorders, Genetic Disorders, Infectious Diseases)
5.2.4. By Region
5.2.5. By Company (2024)
5.3. Market Map
6. NORTH AMERICA ANTISENSE AND RNAI THERAPEUTICS MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Technology
6.2.2. By Route of Administration
6.2.3. By Application
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Antisense And RNAi Therapeutics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Technology
6.3.1.2.2. By Route of Administration
6.3.1.2.3. By Application
6.3.2. Canada Antisense And RNAi Therapeutics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Technology
6.3.2.2.2. By Route of Administration
6.3.2.2.3. By Application
6.3.3. Mexico Antisense And RNAi Therapeutics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Technology
6.3.3.2.2. By Route of Administration
6.3.3.2.3. By Application
7. EUROPE ANTISENSE AND RNAI THERAPEUTICS MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Technology
7.2.2. By Route of Administration
7.2.3. By Application
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Antisense And RNAi Therapeutics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Technology
7.3.1.2.2. By Route of Administration
7.3.1.2.3. By Application
7.3.2. France Antisense And RNAi Therapeutics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Technology
7.3.2.2.2. By Route of Administration
7.3.2.2.3. By Application
7.3.3. United Kingdom Antisense And RNAi Therapeutics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Technology
7.3.3.2.2. By Route of Administration
7.3.3.2.3. By Application
7.3.4. Italy Antisense And RNAi Therapeutics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Technology
7.3.4.2.2. By Route of Administration
7.3.4.2.3. By Application
7.3.5. Spain Antisense And RNAi Therapeutics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Technology
7.3.5.2.2. By Route of Administration
7.3.5.2.3. By Application
8. ASIA PACIFIC ANTISENSE AND RNAI THERAPEUTICS MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Technology
8.2.2. By Route of Administration
8.2.3. By Application
8.2.4. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Antisense And RNAi Therapeutics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Technology
8.3.1.2.2. By Route of Administration
8.3.1.2.3. By Application
8.3.2. India Antisense And RNAi Therapeutics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Technology
8.3.2.2.2. By Route of Administration
8.3.2.2.3. By Application
8.3.3. Japan Antisense And RNAi Therapeutics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Technology
8.3.3.2.2. By Route of Administration
8.3.3.2.3. By Application
8.3.4. South Korea Antisense And RNAi Therapeutics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Technology
8.3.4.2.2. By Route of Administration
8.3.4.2.3. By Application
8.3.5. Australia Antisense And RNAi Therapeutics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Technology
8.3.5.2.2. By Route of Administration
8.3.5.2.3. By Application
9. MIDDLE EAST & AFRICA ANTISENSE AND RNAI THERAPEUTICS MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Technology
9.2.2. By Route of Administration
9.2.3. By Application
9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Antisense And RNAi Therapeutics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Technology
9.3.1.2.2. By Route of Administration
9.3.1.2.3. By Application
9.3.2. UAE Antisense And RNAi Therapeutics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Technology
9.3.2.2.2. By Route of Administration
9.3.2.2.3. By Application
9.3.3. South Africa Antisense And RNAi Therapeutics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Technology
9.3.3.2.2. By Route of Administration
9.3.3.2.3. By Application
10. SOUTH AMERICA ANTISENSE AND RNAI THERAPEUTICS MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Technology
10.2.2. By Route of Administration
10.2.3. By Application
10.2.4. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Antisense And RNAi Therapeutics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Technology
10.3.1.2.2. By Route of Administration
10.3.1.2.3. By Application
10.3.2. Colombia Antisense And RNAi Therapeutics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Technology
10.3.2.2.2. By Route of Administration
10.3.2.2.3. By Application
10.3.3. Argentina Antisense And RNAi Therapeutics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Technology
10.3.3.2.2. By Route of Administration
10.3.3.2.3. By Application
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. GLOBAL ANTISENSE AND RNAI THERAPEUTICS MARKET: SWOT ANALYSIS
14. PORTER'S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. COMPETITIVE LANDSCAPE
15.1. Olix Pharmaceuticals, Inc.
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. GSK plc
15.3. Sanofi Aventis S.A.
15.4. Alnylam Pharmaceuticals, Inc.
15.5. Ionis Pharmaceuticals, Inc.
15.6. Benitec Biopharma Inc
15.7. Silence Therapeutics Inc.
15.8. Arbutus Biopharma Inc.
15.9. Sarepta Therapeutics Inc.
15.10. Percheron Therapeutics Limited.
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
